Phospho-PPP1R12A (T696) Antibody

What is PPP1R12A and what is the significance of its T696 phosphorylation site?

PPP1R12A (Protein phosphatase 1 regulatory subunit 12A), also known as MYPT1 (Myosin phosphatase target subunit 1), is a key regulatory component of the myosin phosphatase complex. This complex consists of three primary subunits: a catalytic subunit (PP1c-delta), a large regulatory subunit (MYPT/PPP1R12A), and a small regulatory subunit (sm-M20).

The phosphorylation at threonine 696 (T696) represents a critical regulatory mechanism for myosin phosphatase activity. Phosphorylation at this site results in inhibition of the phosphatase complex. The T696 site is particularly important because:

• It serves as an inhibitory phosphorylation site that regulates downstream actin-myosin interactions

• It functions in opposition to PKG-mediated phosphorylation at T695, which activates the Mypt1 complex

• T696 phosphorylation is mediated by Rho-kinase (activated by GTP.RhoA), leading to inactivation of myosin phosphatase

• Its phosphorylation status directly impacts smooth muscle contraction, cell adhesion, and migration mechanisms

Research has demonstrated that this regulatory site is critical for understanding cellular processes related to cytoskeletal dynamics and has significant implications for multiple disease states.

What are the primary applications of Phospho-PPP1R12A (T696) antibodies in research?

Phospho-PPP1R12A (T696) antibodies serve as essential tools for investigating the regulatory mechanisms of myosin phosphatase activity. Primary validated applications include:

These antibodies are particularly valuable for:

• Measuring the inhibitory state of myosin phosphatase in various cellular contexts

• Investigating Rho-kinase signaling pathways

• Evaluating cytoskeletal dynamics and cell motility mechanisms

• Exploring the role of PPP1R12A in disease states, particularly cancer and diabetes research

The antibody's specificity for the phosphorylated form of T696 makes it an excellent tool for distinguishing between active and inactive states of the myosin phosphatase complex .

How should I validate the specificity of Phospho-PPP1R12A (T696) antibody in my experimental system?

Validating antibody specificity is crucial for reliable research outcomes. For Phospho-PPP1R12A (T696) antibody, implement the following comprehensive validation approach:

• Positive controls:

  • Use Jurkat cells treated with Calyculin A (30 minutes at 37°C after serum starvation)

  • This treatment increases phosphorylation at T696, providing a strong positive signal

• Peptide competition assay:

  • Pre-incubate the antibody with a synthetic phosphorylated peptide corresponding to the T696 region

  • Run parallel samples with and without peptide blocking

  • A significant reduction in signal with the blocking peptide confirms specificity

• Phosphatase treatment control:

  • Treat one sample with lambda phosphatase before antibody application

  • Loss of signal confirms phospho-specificity

• Knockdown/knockout validation:

  • Use PPP1R12A siRNA or CRISPR-edited cells

  • Compare signal intensity with control cells

  • Signal reduction in knockdown cells confirms specificity

• Cross-reactivity assessment:

  • Test against related phosphorylation sites (T853 in PPP1R12A)

  • Evaluate detection of PPP1R12B and PPP1R12C, which share homology at this site

Research by Xue et al. demonstrated successful validation in L6 skeletal muscle cells using an inducible knockdown system where PPP1R12A levels were reduced by more than 80%, confirming antibody specificity through corresponding signal reduction .

What are the optimal sample preparation methods for detecting phospho-PPP1R12A (T696) in different experimental contexts?

Sample preparation is critical for preserving phosphorylation status and obtaining reliable results with phospho-PPP1R12A (T696) antibody across different applications:

For Western Blot Analysis:

• Rapidly harvest cells on ice to prevent phosphatase activity

• Use lysis buffer containing:

  • Phosphatase inhibitors (10 mM sodium fluoride, 2 mM sodium orthovanadate)

  • Protease inhibitors (complete cocktail)

  • RIPA or NP-40 buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40)

• Standardize protein loading at 25 μg per lane

• Use 3% BSA (not milk) as blocking agent to prevent non-specific binding

• Include Calyculin A treatment (100 nM for 30 minutes) as a positive control

For Immunohistochemistry:

• Freshly fix tissues in 10% neutral buffered formalin (24 hours)

• Process tissues through standardized paraffin embedding protocol

• Section at 5 μm thickness

• Perform heat-induced epitope retrieval in citrate buffer (pH 6.0)

• Block endogenous peroxidase activity with 3% H₂O₂

• Use serum-free protein block to reduce background

For Immunofluorescence:

• Fix cells with 4% paraformaldehyde (10 minutes at room temperature)

• Permeabilize with 0.1% Triton X-100 (5 minutes)

• Block with 5% normal goat serum

• Incubate with primary antibody at 1:200-1:1000 dilution

• Use secondary antibody conjugated with Alexa Fluor or similar fluorophores

Special Considerations:

• Always include subcellular fractionation controls (Hsp90 for cytoplasm, Calreticulin for membrane)

• For phosphoproteomics, enrich phosphopeptides using titanium dioxide (TiO₂) beads prior to analysis

• When quantifying phosphorylation levels via Phos-tag SDS-PAGE, include untreated controls to distinguish phosphorylation bands

How can Phospho-PPP1R12A (T696) antibody be used to investigate the crosstalk between RhoA signaling and insulin pathways?

The intersection of RhoA signaling and insulin pathways represents a complex regulatory network where Phospho-PPP1R12A (T696) antibody serves as a critical tool for mechanistic investigation. Recent phosphoproteomic studies have revealed significant crosstalk between these pathways:

• Insulin-RhoA-PPP1R12A signaling axis assessment:

  • Utilize the antibody to monitor T696 phosphorylation status in response to:

    • Insulin stimulation (100 nM, time course: 0, 5, 15, 30 minutes)

    • RhoA activators (lysophosphatidic acid, thrombin)

    • Combination treatments to assess pathway interactions

• Quantitative phosphoproteomics approach:

  • Implement the methodology described by Xue et al., who identified 698 phosphorylation sites affected by PPP1R12A knockdown

  • Design an experimental matrix:

    Condition	Insulin	RhoA Inhibitor (Y-27632)	PP1 Inhibitor (Calyculin A)
    Control	-	-	-
    Insulin	+	-	-
    RhoA-	-	+	-
    RhoA-/Ins	+	+	-
    PP1-	-	-	+
    PP1-/Ins	+	-	+

• AKT1-PPP1R12A feedback loop analysis:

  • AKT1 has been validated as a novel PP1c-PPP1R12A substrate through K-BIPS methodology

  • AKT1 silencing increases inhibitory phosphorylation of PPP1R12A at T696

  • Design experiments to examine this reciprocal regulation:

    • Transfect cells with AKT1 siRNA, constitutively active AKT1, or kinase-dead AKT1

    • Assess T696 phosphorylation levels via western blot

    • Compare with total PPP1R12A levels and phosphorylation at alternative sites (T853)

• Cytoskeletal remodeling assessment:

  • Monitor actin stress fiber formation in parallel with T696 phosphorylation

  • Combine with live-cell imaging to correlate phosphorylation status with cytoskeletal dynamics

  • Quantify changes in focal adhesion composition and turnover rates

What role does phosphorylation of PPP1R12A at T696 play in cancer progression, and how can the antibody be applied in cancer research?

Phosphorylation of PPP1R12A at T696 has emerged as a significant regulatory mechanism with implications for cancer progression through multiple pathways. The Phospho-PPP1R12A (T696) antibody provides valuable insights in cancer research:

• Altered PPP1R12A expression and phosphorylation in cancer tissues:

  • Studies have shown PPP1R12A is significantly downregulated in prostate cancer (PCa) compared to normal tissues

  • Immunohistochemistry analysis revealed:

    • Stronger PPP1R12A immunostaining in benign prostate tissues compared to PCa tissues

    • Correlation between PPP1R12A expression and Gleason score in PCa

  • The antibody enables quantitative assessment of phosphorylation status across:

    • Primary tumors vs. normal tissues

    • Different cancer stages and grades

    • Metastatic vs. non-metastatic samples

• PPP1R12A as a prognostic biomarker:

  • Research by Lin et al. and Liang et al. demonstrated:

    • PPP1R12A can inhibit angiogenesis and tumor growth in PCa

    • Combined with CD31, PPP1R12A expression serves as a significant prognostic factor

  • Develop a standardized IHC scoring system using the antibody to:

    • Quantify phospho-T696/total PPP1R12A ratio

    • Correlate this ratio with patient outcomes

    • Integrate with other molecular markers for comprehensive prognostic assessment

• Mechanistic investigation of T696 phosphorylation in cancer signaling:

  • PPP1R12A-related differentially expressed genes (DEGs) analysis revealed:

    • 340 PPP1R12A-related DEGs in PCa (338 upregulated, 2 downregulated)

    • Enrichment in pathways related to:

      • Calcium ion concentration regulation

      • Fibroblast migration

      • ECM components and cell adhesion

      • Angiogenesis and tumor growth

• Therapeutic targeting assessment:

  • Screen compounds that modulate T696 phosphorylation status

  • Use the antibody to monitor treatment efficacy in:

    • Patient-derived xenografts

    • 3D organoid cultures

    • Clinical trial samples

A five-gene signature based on PPP1R12A and metabolism-related genes has been constructed to predict the prognosis of PCa patients . Using the Phospho-PPP1R12A (T696) antibody to assess the phosphorylation status in these signature-stratified patient cohorts could provide additional layer of prognostic information and potential therapeutic implications.

What are common issues encountered with Phospho-PPP1R12A (T696) antibody applications and how can they be resolved?

Researchers frequently encounter several technical challenges when working with Phospho-PPP1R12A (T696) antibody. Here are systematic approaches to identify and resolve these issues:

1. High Background Signal in Western Blots:

2. Weak or No Signal:

3. Multiple Bands or Unexpected Band Sizes:

4. Inconsistent IHC/IF Staining:

Research by Zhang et al. demonstrated that subcellular fractionation could help resolve localization issues, showing shuttling of PPP1R12A between nuclear and cytoplasmic compartments under different treatment conditions . Include appropriate subcellular markers (Hsp90 for cytoplasm, Calreticulin for membrane) as internal controls .

How should research data using Phospho-PPP1R12A (T696) antibody be normalized and quantified for meaningful comparison across experiments?

Proper normalization and quantification are essential for generating reliable and reproducible data when using Phospho-PPP1R12A (T696) antibody. Implement these methodological approaches:

1. Western Blot Quantification Strategy:

• Ratio-based normalization:

  • Always measure phospho-T696 signal relative to total PPP1R12A

  • Calculate phospho/total ratio to account for variations in total protein expression

  • Use this approach to avoid misinterpretation of changes in phosphorylation vs. expression

• Loading control considerations:

  • Primary normalization: total PPP1R12A

  • Secondary normalization: housekeeping proteins (β-actin, GAPDH, α-tubulin)

  • For enhanced accuracy: total protein normalization via Ponceau S or REVERT staining

• Quantification methodology:

  • Use linear range capture settings for all images

  • Apply rolling ball background subtraction

  • Measure integrated density values

  • Report results as fold change relative to control condition

2. Immunohistochemistry and Immunofluorescence Quantification:

Lin et al. utilized this approach to demonstrate correlation between PPP1R12A expression and PCa outcomes .

3. Phosphoproteomic Data Analysis:

• Label-free quantification:

  • Normalize to multiple reference phosphopeptides (identified across all samples)

  • Calculate fold changes using log2 transformation

  • Apply statistical testing with multiple comparison correction

  • Set significance threshold at p<0.05 and fold change >1.5

• Pathway analysis integration:

  • Group phosphoproteins by signaling pathways

  • Calculate pathway enrichment scores

  • Visualize using heat maps and interaction networks

4. Experimental Design for Statistical Validity:

• Minimum of three biological replicates

• Include technical replicates within each biological sample

• Implement randomization and blinding where applicable

• Use appropriate statistical tests (t-test for two conditions, ANOVA for multiple conditions)

• Report effect sizes along with p-values

For mechanistic studies linking PPP1R12A to AKT1, researchers have validated findings using multiple complementary approaches including K-BIPS chemoproteomics and Phos-tag SDS-PAGE, which showed 37±9% and 34±6% reductions in phosphorylated AKT1 bands between untreated and Dox-treated samples .

How can the Phospho-PPP1R12A (T696) antibody be utilized to investigate the role of PPP1R12A in metabolic disorders, particularly insulin resistance and type 2 diabetes?

Recent phosphoproteomic studies have revealed PPP1R12A's unexpected role in insulin signaling pathways, opening new research avenues for metabolic disorders:

• Investigation of PPP1R12A in insulin-sensitive tissues:

  • Apply the Phospho-PPP1R12A (T696) antibody to compare phosphorylation levels across:

    • Skeletal muscle biopsies from healthy vs. insulin-resistant subjects

    • Adipose tissue in normal vs. diabetic models

    • Hepatic tissues under various metabolic conditions

  • Correlate T696 phosphorylation status with:

    • Glucose uptake measurements

    • Insulin receptor substrate (IRS) phosphorylation

    • Glycogen synthesis rates

• Mechanistic link to insulin signaling components:

  • Research by Xue et al. identified PPP1R12A as a novel endogenous interaction partner with insulin receptor substrate 1 (IRS1)

  • PPP1R12A knockdown significantly increased phosphorylation of IRS1 at S522 under insulin stimulation

  • Design experimental approach:

    • Immunoprecipitate IRS1 and probe for co-precipitation with PPP1R12A

    • Assess how T696 phosphorylation affects this interaction

    • Manipulate T696 phosphorylation (using kinase inhibitors or phosphomimetic mutants) and measure impact on insulin signaling

• Signaling pathway integration:

  • Ingenuity Pathway Analysis of PPP1R12A-affected phosphoproteins revealed enrichment in pathways related to insulin signaling :

    • Insulin receptor signaling

    • mTOR signaling

    • RhoA signaling

    • ERK/MAPK signaling

  • Develop a multi-antibody panel to monitor:

    • PPP1R12A-T696 phosphorylation

    • Key nodes in insulin signaling

    • Metabolic enzyme activation status

• Potential therapeutic target assessment:

  • Screen compounds that modulate T696 phosphorylation

  • Measure metabolic outcomes:

    • Glucose uptake and metabolism

    • Lipid accumulation and oxidation

    • Insulin sensitivity markers

What are emerging applications of Phospho-PPP1R12A (T696) antibody in understanding cytoskeletal regulation during embryonic development?

The regulation of cytoskeletal dynamics during embryonic development represents a frontier area where Phospho-PPP1R12A (T696) antibody can provide valuable insights:

• Developmental expression and phosphorylation patterns:

  • Research by Duan et al. demonstrated alternative splicing of ppp1r12a/mypt1 in zebrafish produces transcript variant 202 (tv202)

  • Implement developmental time-course analysis:

    • Apply the antibody to track T696 phosphorylation across key developmental stages

    • Correlate with morphogenetic movements and tissue organization

    • Compare with expression patterns of other transcript variants

• Convergent extension during gastrulation:

  • Zebrafish studies showed ppp1r12a knockdown results in severe gastrulation defects

  • Experimental approach:

    • Monitor T696 phosphorylation during convergent extension movements

    • Correlate phosphorylation status with measurements of:

      • Notochord width

      • Body axis elongation

      • Cell intercalation dynamics

    • Use quantitative measures like "the angle between the leading edge of the prechordal plate and the end of the notochord"

• Tissue-specific roles during organogenesis:

  • Apply the antibody in combination with tissue-specific markers:

    • Neural markers (pax2.1, dlx3)

    • Notochord marker (shh)

    • Prechordal plate marker (hgg1)

  • Assess differences in T696 phosphorylation across developing tissues

  • Correlate with cell shape changes and tissue architecture

• Subcellular localization dynamics:

  • Recent research revealed nucleo-cytoplasmic shuttling of PPP1R12A

  • Implement high-resolution imaging to track:

    • Subcellular distribution of phosphorylated vs. total PPP1R12A

    • Temporal changes during developmental transitions

    • Co-localization with cytoskeletal structures and adhesion complexes

Developmental rescue experiments have demonstrated that ppp1r12a-tv202 mRNA can partially rescue the gastrulation defect in ppp1r12a morphants, suggesting functional conservation despite structural differences . The Phospho-PPP1R12A (T696) antibody could be used to determine if this rescue correlates with restored phosphorylation patterns, providing mechanistic insights into the developmental regulation of PPP1R12A activity.

What are the key technical specifications and validation parameters for commercially available Phospho-PPP1R12A (T696) antibodies?

Below is a comprehensive comparison of commercially available Phospho-PPP1R12A (T696) antibodies based on the search results data:

What are the phosphorylation patterns and interactions of PPP1R12A at T696 across different cell types and conditions?

The following table synthesizes research findings on phosphorylation patterns and regulatory interactions of PPP1R12A at T696: